Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Fig. 3

The anti-cath-D F1 and E2 antibodies accumulate in MDA-MB-231 tumor xenografts, reduce tumor growth in vivo and improve survival. a SPECT/CT analysis. MDA-MB-231 cells were xenografted subcutaneously in the right flank of nude mice. When tumor volume reached 150 mm3, mice received one intra-peritoneal injection of 177Lu- F1 or 177Lu- E2. Representative SPECT/CT images at 24, 48 and 72 h post-injection of 177Lu- F1 (left panels) and 177Lu- E2 (right panels). * shows tumors. b Tumor growth. MDA-MB-231 cells were subcutaneously injected in nude mice. When tumor volume reached 50 mm3, mice were treated with F1 (n = 6) or E2 (n = 6) (15 mg/kg), or NaCl (CTRL; n = 8) three times per week for 32 days. Mice were sacrificed when tumor volume reached 2000 mm3. Tumor volume (in mm3) is shown as the mean ± SEM. ***, P < 0.001 for F1; ** P = 0.002 for E2 (mixed-effects ML regression test). c Mean tumor volumes at day 55. ***, P = 0.0005 for F1; **, P = 0.0026 for E2 (t test); mean ± SEM. d Kaplan-Meier survival analysis. ***, P = 0.0005 for F1; **, P = 0.0016 for E2

Back to article page